NCT07196501
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 8 words
- Interventions modified
- Study sites: 60 to 61
- Study title revised
- Minor Trial sites expanded: 45 → 60 locationsv4
- Minor Study sites: 31 to 45v3
- Minor Study sites: 4 to 31v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time from Randomization to Relapse
Timeframe: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)
Arms and interventions
Open-label Treatment Period: OsavampatorExperimental
Participants will be treated with osavampator during the open-label treatment period.
Randomized Double-blind Maintenance Period: OsavampatorExperimental
Participants will be randomized to receive osavampator during the randomized double-blind maintenance period.
Randomized Double-blind Maintenance Period: PlaceboExperimental
Participants will be randomized to receive matching placebo during the randomized double-blind maintenance period.
Drugs: Osavampator, Placebo
Sites
61 sites in 11 countries
United States 24, Canada 5, Bulgaria 4, Italy 4, South Korea 4, Spain 4, Taiwan 4, Australia 3, Estonia 3, Poland 3, Serbia 3